Institute for Aging Research at the Albert Einstein College of Medicine
Dr. Nir Barzilai is a preeminent leader in geroscience, demonstrating in his studies that aging has its
own biology that drives age-related diseases, a process that can be targeted. He is the Ingeborg and
Ira Leon Rennert Chair of Aging Research, a professor in the Departments of Medicine and
Genetics, the director of the Institute for Aging Research at the Albert Einstein College of Medicine,
the Director of the National Institutes of Health’s (NIH) Nathan Shock Centers of Excellence in the
Basic Biology of Aging. He is leading an international effort to approve drugs targeting aging.
Targeting Aging with METformin (TAME) is a specific study designed to prove the concept that multi-
morbidities of aging can be delayed by metformin; working with the FDA to approve this approach,
which will serve as a template for future efforts to delay aging and its diseases in humans, and also
has a biomarker arm. Dr. Barzilai is also the Scientific Director and on the board of the American
Federation for Aging Research, where he leads its biomarker effort (FAST). He is the Executive of
the Longevity Biotech Association (LBA) and on the Healthy Longevity Medicine Society council. He
is also a founder of CohBar Inc. and LifeBioscience biotech. He authorizes Age Later: Health Span,
Life Span, and the New Science of Longevity.